NovaBridge Biosciences
As of Oct 22, 2026, NovaBridge Biosciences is in Stage 4, the downtrend phase, now in week 5 (since Sep 22, 2026). It closed at $1.33, 73.1% below its 52-week high and below its 200-day average, which is falling.
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NBP early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NBP among Biotechnology441st of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …441 | NBP | Stage 4 · wk 5 | 14 | −13.1% |
NovaBridge Biosciences: quick answers
What stage is NovaBridge Biosciences in?
As of Oct 22, 2026, NovaBridge Biosciences (NBP) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 22, 2026 and is in week 5. What the four stages mean
Is NovaBridge Biosciences in an uptrend?
No. NovaBridge Biosciences is in a Stage 4 downtrend. It trades 41.1% below its 200-day average, which is falling.
How far is NovaBridge Biosciences from its 52-week high?
NovaBridge Biosciences closed at $1.33 on Oct 22, 2026, 73.1% below its 52-week high of $4.95. Its 52-week low is $1.26.
How has NovaBridge Biosciences performed over the past year?
As of Oct 22, 2026, NovaBridge Biosciences is down 74.1% over the past year and down 68.9% so far in 2026.
Which sector and industry is NovaBridge Biosciences in?
NovaBridge Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.